Lupin Limited
Lupin Limited (India) holds 93 active US FDA Type II Drug Master Files and 82 inactive, has DMF or CEP filings on record for 40 active ingredients and is linked to 7 FDA-registered manufacturing sites. 36 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Lupin Limited: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/lupin-limited
Overview
Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, specializing in the manufacture and sale of branded and generic formulations, active pharmaceutical ingredients (APIs), and biotechnology products. Established in 1968 by Dr. Desh Bandhu Gupta, the company has expanded its presence across over 100 countries, focusing on therapeutic areas such as cardiovascular, anti-tuberculosis, and diabetology.
Core services & business areas
Therapeutic areas
Active ingredients with DMF or CEP filings
Substances for which Lupin Limited holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
Lupin Limited holds 93 active (175 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- CHOLIC ACIDActive2026-04-10
- CEPHALEXIN USP (ENZYMATIC)Active2025-03-13
- ALBUTEROL SULFATEActive2024-04-12
- UMECLIDINIUM BROMIDEActive2023-04-11
- FLUTICASONE FUROATEActive2022-11-21
- VILANTEROL TRIFENATATEActive2022-03-18
- CEFUROXIME ACIDActive2021-04-12
- BICTEGRAVIR SODIUM (MICRONIZED)Active2021-04-09
- TOLVAPTANActive2019-05-03
- TENOFOVIR ALAFENAMIDE FUMARATE (PROCESS-B)Active2019-03-19
- BREXPIPRAZOLEActive2019-02-07
- SITAGLIPTIN PHOSPHATE ANHYDROUS USPActive2018-04-12
- RIFAXIMIN (PROCESS B)Active2017-10-17
- VARENICLINE TARTRATEActive2017-04-13
- VORTIOXETINE HYDROBROMIDEActive2017-03-23
- HYDROCORTISONE VALERATE USPActive2016-12-30
- METHYLPREDNISOLONE SODIUM SUCCINATEActive2016-04-15
- EZETIMIBE USP (PROCESS-C)Active2016-04-14
- OSELTAMIVIR PHOSPHATE USPActive2016-04-13
- PIRFENIDONEActive2016-04-13
- TESTOSTERONE USPActive2016-04-11
- LEVOTHYROXINE SODIUM USPActive2016-03-22
- TIOTROPIUM BROMIDE MONOHYDRATEActive2016-01-20
- FLUTICASONE PROPIONATE USPActive2015-12-10
- PITAVASTATIN SODIUMActive2015-11-06
- DULOXETINE HYDROCHLORIDE USP (PROCESS B)Active2015-03-27
- VILAZODONE HYDROCHLORIDEActive2014-07-30
- EZETIMIBE USP (PROCESS-B)Active2014-04-14
- PITAVASTATIN CALCIUMActive2013-07-23
- ILOPERIDONEActive2013-06-14
- TRAVOPROST USPActive2013-04-19
- ROSUVASTATIN CALCIUMActive2013-04-09
- CALCIUM L-5-METHYLTETRAHYDROFOLATE USPActive2013-03-12
- LOSARTAN POTASSIUM USP (CRYSTALLINE)Active2012-04-04
- ESTRADIOL HEMIHYDRATE USPActive2012-04-02
- ESTRADIOL VALERATE USPActive2012-03-30
- TENOFOVIR DISOPROXIL FUMARATEActive2012-03-27
- NORGESTREL USPActive2011-03-30
- DESOGESTRELActive2010-04-12
- GATIFLOXACINActive2010-04-08
- CELECOXIB USPActive2010-04-08
- ABACAVIR SULFATE USPActive2010-04-08
- DROSPIRENONE USPActive2010-01-12
- ARMODAFINILActive2009-10-27
- EMTRICITABINEActive2009-09-18
- NORGESTIMATE USPActive2009-04-15
- LEVONORGESTREL USPActive2009-03-31
- NORETHINDRONE ACETATE USPActive2009-03-26
- ETHINYL ESTRADIOL USPActive2009-03-13
- NORETHINDRONE USPActive2009-02-25
Showing the 50 most relevant of 175 Drug Master Files (active first). The full list is in the FDA DMF list.
Registered manufacturing sites (7)
Physical sites registered with the US FDA and resolved to Lupin Limited, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
- Lupin LimitedPune, India · Analytical testing · Drug manufactureSite GMP match
- LUPIN LIMITEDTarapur, India · API manufacture
- LUPIN LIMITEDAnkleshwar, India · API manufacture
- LUPIN LIMITEDMandideep, India · API manufacture
- LUPIN LIMITEDMandideep, India · API manufacture
- LUPIN LIMITEDDhar, India · API manufacture
- LUPIN LIMITEDSalcette, India · Drug manufacture · PackagingSite GMP match
FDA compliance signals
36 FDA enforcement records linked to this company.
- 4832025-09-16
Validation lacking for sterile drug products
- 4832025-09-16
Investigations of discrepancies, failures
- 4832025-09-16
Procedures for sterile drug products
- 4832025-09-16
Environmental Monitoring System
- 4832025-09-16
Computer control of master formula records
- 4832025-09-16
Valid stability test methods
- 4832025-07-17
Testing Each Component for Conformity with Specs
- 4832025-07-17
Investigations of discrepancies, failures
- 4832025-07-17
Procedures for sterile drug products
- 4832025-07-17
Written in-process control procedures
- 4832025-07-17
Investigations of discrepancies, failures
- 4832025-07-17
Written in-process control procedures
- 4832025-07-17
Air Supply
- 4832023-07-11
Sample identification and other information
- 4832023-07-11
Complete Test Data
- warning_letter2022-09-27
FDA Warning Letter (drug product)
- warning_letter2019-09-10
FDA Warning Letter (drug product)
- 4832019-01-25
Equipment Design, Size and Location
- 4832019-01-25
Investigations of discrepancies, failures
- 4832019-01-25
Following/documenting laboratory controls
- 4832019-01-25
Computer control of master formula records
- 4832019-01-25
Written record of complaint to include findings, follow-up
- 4832019-01-25
Training , Education , Experience overall
- 4832019-01-18
Failure to develop written procedures
- 4832019-01-18
Failure to maintain records
- 4832019-01-18
Late submission of 15-day report
- 4832019-01-18
Failure to report non-alert ADEs
- recall — Class II2017-11-29
Presence of foreign tablets/capsules: This product lot is being recalled due to a pharmacy complaint where one Duloxetine Delayed Release Capsule, 30mg was found in a Pravastatin Sodium Tablets USP, 40mg bottle.
- warning_letter2017-11-06
FDA Warning Letter (drug product)
- warning_letter2017-11-06
FDA Warning Letter (drug product)
- recall — Class III2016-09-28
Labeling: Incorrect or Missing Lot and/or Expiration Date
- recall — Class III2016-09-14
CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose intermediates failed specifications.
- recall — Class III2016-09-14
CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose intermediates failed specifications.
- 4832015-04-03
Scientifically sound laboratory controls
- 4832015-04-03
Following/documenting laboratory controls
- warning_letter2009-05-07
FDA Warning Letter (drug product)
Is this Lupin Limited?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Related companies
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.